New Product Newswire

Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.

With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.

Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.

This new, nonprescription therapy expands eye relief options for patients in need of apraclonidine eye drop formulations.

The oral tablet formulation was approved for adults with weakened immune systems who have not responded to other therapy.

Teva Pharmaceuticals’ new olanzapine option is the first once-monthly subcutaneous injectable on the market for schizophrenia.